Interview with Jonathan Zhu, General Manager, Celgene China
Celgene is a relative newcomer to China. What’s the story behind how the company entered the market, and how did you yourself come to manage the local operations? I officially…
Address: No. 222, Huangpu District, Shanghai Yan’an East Road
, Bund Center, 1102 – Room 1104
Zip: 200002 ,China
Tel: +86 216 133 9333
The new base is committed to providing innovative medicines that can really change the life for patients. Our mission is to build a global enterprise based biopharmaceutical, while focusing on the exploration, development, and commercialization of pharmaceutical products for the treatment of cancer and other serious diseases such as immune and inflammatory.
Major medical centers about 300 a number of new base compounds of clinical trials. Compounds of these studies are for blood and solid tumor cancer patients suffering from an incurable research, including multiple myeloma, bone marrow hyperplasia anomaly syndrome, chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL ), myelofibrosis, small cell lung cancer and prostate cancer.
As committed to the clinical achievements, we are equally committed to providing patient support, which is the guiding principle of the new base. We believe that all patients should be given the opportunity to benefit from our research. New base by the industry-leading program patients were placed in the first, to provide information, support, and our innovative therapies.
Revlimid
Celgene is a relative newcomer to China. What’s the story behind how the company entered the market, and how did you yourself come to manage the local operations? I officially…
Dr Kai Lamottke, co-founder and MD of Bicoll GmbH, Munich, and since 2001, GM and board member of Bicoll Biotechnology (Shanghai) Co. Ltd discusses Bicoll’s presence in both the Chinese…
Jim Xu, GM of Medidata China, shares the importance of the China market to Medidata Solutions, the global leader in cloud services and solutions to the life sciences industry; his…
Dr. Chris Lu, CEO and cofounder of Laekna Therapeutics, shares Laekna’s ambition to deliver cures and improve the quality of life of patients globally, captured by the word ‘Laekna’, which…
Tony Acciarito, President of Thermo Fisher Scientific China, explains how he is delivering the company’s mission of ‘enabling our customers to make the world healthier, cleaner and safer’ in China,…
Zheru Zhang and Jielun Zhu of I-Mab Biopharma, shares their vision for the ambitious biotech company looking to develop their dual-pronged strategy of in-licensing ‘fast-to-market’ assets for their China portfolio…
Junshi Biosciences is an innovation-driven biopharmaceutical company with a focus on discovery and innovative drugs. Dr Li Ning, CEO, discusses being the first Chinese company to successfully launch a domestically-developed…
Kai Zhang, founder and chairman, and Sonia Wang, CEO, of Chinese respiratory technology specialist Omni Pharmaceuticals, discuss the respiratory market in China, how Omni plans to introduce four respiratory drugs…
Transcenta’s Xueming Qian outlines the new company’s origins, the space it seeks to fill within the highly competitive Chinese oncology market, and where Chinese biotech stands globally in 2019. …
Boehringer Ingelheim veteran executive Felix Gutsche shares the first impressions of the China market since he joined in January 2019; the strategic significance of the market as one of the…
Multinational pharma companies have been setting up shop in China ever since Novartis launched its Chinese affiliate in 1987, with other pharma giants following in its footsteps soon after, eager…
Gaobo Zhou is Partner and co-leader of the Healthcare Practice in China and has been with McKinsey for over a decade, Gaobo discusses the changes occurring within the complex and…
“Mental health is currently a major problem in China, and will become an ever greater problem unless effective interventions are put in place.” Mental Health has Long Been a…
See our Cookie Privacy Policy Here